Fritextsökning
Artiklar per år
Innehållstyper
-
Antikropp mot leukemi
Genmab och Glaxosmithkline har ansökt om marknadsgodkännande hos EMEA för det biologiska leukemiläkemedlet Arzerra, med aktiv substans ofatumumab.
-
IVF ökar inte risk för cancer
En ny dansk studie visar att fertilitetsbehandling inte ökar risken för äggstockscancer. Över femtiotusen kvinnor deltog i studien som är den största hittills av sitt slag.
-
Liten docka kan göra stor nytta
Japanska forskare har tillverkat en levande dockmodell av levercancerceller och collagen. Dockan kan bli ett nytt redskap för att testa nya läkemedel i en miljö som liknar den inne i människokroppen.
-
Helge Sander: "Fler kvinnor behövs"
- Det är något fel när det ena könet i stort sett väljer bort en karriär som forskare, säger Danmarks forskningsminister. Idag håller han rundabordssamtal för att diskutera varför kvinnliga forskare missgynnas. Han välkomnar alla lösningar, utom en.
-
Roche sänker budet på Genentech
I juli ifjol var budet 89 dollar per aktie. Då sa Genentechs styrelse nej tack. Nu meddelar läkemedelsjätten att man sänker budet och vänder sig direkt till småägarna.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.
-
Vattenfall is firing with biomass
Vattenfall will provide Denmark with electricity by means of biomass.
-
Finnish-Dutch engineering cooperation continues
The University of Helsinki and ASM International renew a fice year research agreement on Atomic Layer Deposition.
-
Top modern lab to Sahlgrenska
The Sahlgrenska Science Park will soon open the doors to a brand new wet laboratory.
-
Medtech companies find new beam technique
The medtech companies Raysearch and Nucletron expand collaboration with two new solutions for radiation treatment planning.
-
Abbott expands by acquisition
An acquisition gives Abbott a leadership position in another large and growing medical device segment.
-
Dupont gets new business manager
The Swedish API manufacturer Dupont Chemoswed has appointed a new business development manager.
-
Transatlantic cooperation for healthier food
Danish and American scientists are going to work together to find ways to fight malnutrition and life style disease like obesity in the western world.
-
Transatlantic cooperation for healthier food
Danish and American scientists are going to work together to find ways to fight malnutrition and life style disease like obesity in the western world.
-
Finnish Innovation Fund gets new leader
The Supervisory Board of the Finnish Innovation Fund Sitra has appointed members of the Board, including a new president.
-
Medicult disclaims Swedish offer
The Norwegian company Medicult's Board is highly sceptical to the yesterday announced Vitrolife offer.
BREAKING